Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical trial adolescent cohort, establish...
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer...
Issues 2024 financial guidanceWARSAW, Ind., Jan. 08, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a...
Robert M. Brenner Robert M. Brenner, M.D., Chief Medical Officer William D. Turner William D. Turner, Chief Development Officer BRISBANE,...
Company provides year-end health plan membership guidance, strengthens conviction of path to adjusted EBITDA breakeven in 2024ORANGE, Calif., Jan. 08,...
First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study to evaluate safety and PK/PD of...
“Life Couriers acquires RLG to create the global logistic leader for radiopharmaceuticals transportation”. Philippe Sueur, Isovital President stated: « Significant efforts were...
Company reports preliminary placement results of twelve Focal One Systems, inclusive of ten capital sales LYON, France, January 8, 2024...
Portage, Michigan, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it surpassed $20 billion in annual sales...
LAKEWOOD, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us”, or “our”), a global leader...
Six Presentations Highlight Landos’ Leadership in Targeting Immunometabolic Pathways as Novel Treatments for Autoimmune Diseases with Focus on Ulcerative ColitisNEW...
SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer...
Company achieved significant commercial progress in 2023 IBSRELA® now expected to generate greater than $1.0 billion in annual U.S. net...
Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of...
Revenue expected to be between $195 and $205 million, represents a 31% to 38% increase over the midpoint of 2023...
iPSC-derived CAR T-cell Product Candidate Incorporates Seven Synthetic Controls of Cell Function including a Novel HER2-targeted Antigen Binding Domain Phase...
Dr. Adi Hoess to step down as CEO and Management Board MemberDr. Andreas Harstrick appointed Interim CEOStrategic restructuring reducing headcount...
Leading Investors BOLD Capital, Digitalis Ventures, and Hill Creek Partners drive financial milestone Financing to expedite conditional FDA approval of...
Combined organizations have helped more than 1 million kids Expands Specialty Bracing Division with pediatric orthotic management business offering leading technology...
MENLO PARK, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...